MAP 0.00% 18.0¢ microba life sciences limited

Ann: NWR Virtual Healthcare Conference Presentation, page-2

  1. 9,775 Posts.
    lightbulb Created with Sketch. 961
    In the presentaion today professor Trent Munro confirmed that the first in vitro screening results for autoimmune diseases in partnership with Ginko Bioworks have been received and will be reported to market this month ( sometime over next 10 days ).

    Interesting that the first FDA approved Rebiotix faecal donor derived enema product relies on actual donors as does the next to be FDA approved Seres faecal donor derived ORAL capsule drug product which makes them very problematical. Microba's future products will be replicating the applicable microbiome as lab manufactured which makes it hugely more scalable and more accurately targeted.
 
watchlist Created with Sketch. Add MAP (ASX) to my watchlist
(20min delay)
Last
18.0¢
Change
0.000(0.00%)
Mkt cap ! $80.61M
Open High Low Value Volume
17.5¢ 18.0¢ 17.5¢ $17.99K 102.8K

Buyers (Bids)

No. Vol. Price($)
2 35882 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 100000 1
View Market Depth
Last trade - 12.44pm 20/06/2024 (20 minute delay) ?
MAP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.